Allogene Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 2830 allogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics, Inc.

CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot - Sep 15th, 2026 5:11 am
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? - Sep 11th, 2026 9:30 am
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts - Sep 2nd, 2026 6:32 am
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - Sep 2nd, 2026 6:30 am
Allogene Therapeutics Announces Participation in September Investor Conference - Aug 31st, 2026 6:30 am
Allogene (ALLO) Q2 2026 Earnings Call Transcript - Aug 19th, 2026 2:58 pm
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Aug 17th, 2026 7:40 am
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - Aug 13th, 2026 11:47 am
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says - Aug 13th, 2026 9:33 am
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary - Aug 13th, 2026 6:30 am
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... - Aug 12th, 2026 11:01 pm
Allogene Therapeutics Q2 Earnings Call Highlights - Aug 12th, 2026 4:04 pm
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update - Aug 12th, 2026 2:05 pm
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update - Aug 4th, 2026 6:30 am
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma - Jul 29th, 2026 6:30 am
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors - Jul 15th, 2026 6:30 am
Kyverna Therapeutics Sinks 13%: Here’s Why - Jul 10th, 2026 1:59 pm
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Jun 27th, 2026 11:05 pm